Samsara BioCapital, LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001744967
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2026 · 24 positions · Total reported value $1.22B · Top-10 concentration 90.5% · Updated 2026-10-24
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
Turnover: 42.3% · 4 new · 5 cut · 2 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +10.6% · vs SPY -4.2% · Prev Value $1.03B — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2026 13F filing, Samsara BioCapital, LLC disclosed 24 equity positions with a combined reported value of $1.22B. The filing implies a focused portfolio: its ten largest positions account for 90.5% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2026 were SRRK ($379.37M), ALMS ($178.55M), MLYS ($158.40M). By sector, the heaviest allocations are Health Care 94.5%, Industrials 5.5%. Versus the prior quarter, allocation shifted toward Industrials (+5.5pp) and away from Other (-0.7pp), Health Care (-4.8pp).
Versus the prior quarter, Samsara BioCapital, LLC opened 4 new positions, trimmed 5 and fully exited 2, a turnover rate of 42.3% of positions. The portfolio's overlap with the prior quarter was 77% of names.
The largest new positions opened in Q2 2026 were ALMR ($67.19M), PBLS ($15.22M), ARTV ($9.26M).
Of the 2 positions fully exited versus the prior quarter, the largest were ACLX ($6.99M), PVLA ($4.79M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2026)
Insider Transactions (Form 4)
Latest Samsara BioCapital, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Samsara BioCapital, LLC files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 24 positions worth $1.22B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- SEC registration: 801-113741 (status: Approved), registered 2018-07-27
- Regulatory AUM (Form ADV): $2.17B as of 2026-06-26
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 3 private funds
- Website: samsaracap.com
Portfolio Structure
- 24 positions · $1.22B reported value (Q2 2026)
- Top 10 holdings = 90.5% of reported value
- Largest position: SRRK (SCHOLAR ROCK HLDG CORP) at 31.2%
- Average position size: $50.73M
Sector Tilt
- Health Care 94.5%
- Industrials 5.5%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 4 new, 2 added, 5 reduced, 2 exited
- 13 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
AI Rebalance Analysis
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
6.90M | $379.37M | 31.16% | Hold | |
| 2 |
|
6.35M | $178.55M | 14.67% | Hold | |
| 3 |
|
5.87M | $158.40M | 13.01% | Hold | |
| 4 |
|
3.15M | $105.46M | 8.66% | Hold | |
| 5 |
|
2.48M | $67.19M | 5.52% | New | |
| 6 |
|
1.72M | $54.00M | 4.44% | Hold | |
| 7 |
|
12.88M | $52.43M | 4.31% | Reduce | |
| 8 |
|
2.11M | $46.97M | 3.86% | Hold | |
| 9 |
|
1.06M | $35.29M | 2.90% | Hold | |
| 10 |
|
6.31M | $23.87M | 1.96% | Add | |
| 11 |
|
736.24K | $16.36M | 1.34% | Reduce | |
| 12 |
|
556.04K | $15.22M | 1.25% | New | |
| 13 |
|
298.50K | $11.24M | 0.92% | Hold | |
| 14 |
|
2.50M | $10.40M | 0.85% | Hold | |
| 15 |
|
3.51M | $9.93M | 0.81% | Hold | |
| 16 |
|
954.86K | $9.26M | 0.76% | New | |
| 17 |
|
10.37M | $7.88M | 0.65% | Add | |
| 18 |
|
600.00K | $7.79M | 0.64% | Hold | |
| 19 |
|
55.09K | $7.34M | 0.60% | Reduce | |
| 20 |
|
1.40M | $6.52M | 0.54% | Reduce | |
| 21 |
|
400.00K | $5.55M | 0.46% | New | |
| 22 |
|
3.43M | $4.80M | 0.39% | Hold | |
| 23 |
|
353.72K | $2.45M | 0.20% | Reduce | |
| 24 |
|
7.22M | $1.19M | 0.10% | Hold | |
Loading forecast…
Holdings Prediction Model
Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.
The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.
Latest-Quarter Accuracy (2026-Q2)
P 90% R 90% F1 90% (modelled on 2026-Q1; 9/10 hit)
Historical Backtest (10 quarters)
Avg precision 84% · recall 84% · F1 84% · avg rank error 1.8 · Top-10 turnover 20%
| Quarter | Prec. | Recall | F1 | Predicted Top 10 | Actual Top 10 |
|---|---|---|---|---|---|
| 2024-Q1 | 70% | 70% | 70% | SRRK · RYZB · CRGX · MLYS · NGNE · ACLX · GRPH · SLRN · NKTX · SYRS | SRRK · CRGX · MLYS · NGNE · NKTX · ACLX · LENZ · LYRA · SLRN · AVDL |
| 2024-Q2 | 80% | 80% | 80% | SRRK · CRGX · MLYS · NGNE · NKTX · ACLX · LENZ · LYRA · SLRN · AVDL | CRGX · MLYS · SRRK · NGNE · ACLX · CLYM · NKTX · LENZ · AVDL · JSPR |
| 2024-Q3 | 90% | 90% | 90% | CRGX · MLYS · SRRK · NGNE · ACLX · CLYM · NKTX · LENZ · AVDL · JSPR | CRGX · MLYS · SRRK · NGNE · ALMS · ACLX · LENZ · NKTX · CLYM · AVDL |
| 2024-Q4 | 70% | 70% | 70% | CRGX · MLYS · SRRK · NGNE · ALMS · ACLX · LENZ · NKTX · AVDL · CLYM | SRRK · CRGX · SEPN · MLYS · NGNE · UPB · LENZ · ALMS · ACLX · ZYME |
| 2025-Q1 | 80% | 80% | 80% | SRRK · CRGX · SEPN · MLYS · NGNE · UPB · LENZ · ALMS · ACLX · ZYME | SRRK · KLRS · MLYS · NGNE · ALMS · PVLA · SEPN · CRGX · LENZ · UPB |
| 2025-Q2 | 100% | 100% | 100% | SRRK · KLRS · MLYS · NGNE · ALMS · PVLA · SEPN · CRGX · LENZ · UPB | SRRK · MLYS · SEPN · KLRS · NGNE · CRGX · UPB · ALMS · LENZ · PVLA |
| 2025-Q3 | 90% | 90% | 90% | SRRK · MLYS · SEPN · KLRS · NGNE · CRGX · ALMS · UPB · LENZ · GOSS | MLYS · SRRK · KLRS · SEPN · NGNE · ALMS · UPB · GOSS · LENZ · AQST |
| 2025-Q4 | 90% | 90% | 90% | MLYS · SRRK · KLRS · SEPN · NGNE · ALMS · UPB · GOSS · LENZ · AQST | SRRK · MLYS · KLRS · SEPN · ALMS · NGNE · IVA · GOSS · UPB · AQST |
| 2026-Q1 | 80% | 80% | 80% | SRRK · MLYS · KLRS · SEPN · ALMS · NGNE · IVA · GOSS · UPB · JBIO | SRRK · MLYS · ALMS · SEPN · KLRS · SGP · NGNE · IVA · STRO · JBIO |
| 2026-Q2 ★ | 90% | 90% | 90% | SRRK · MLYS · ALMS · KLRS · SEPN · SGP · NGNE · STRO · IVA · JBIO | SRRK · ALMS · MLYS · SEPN · ALMR · NGNE · KLRS · SGP · STRO · IVA |
★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.
FAQ
What did Samsara BioCapital, LLC buy in 2026-Q2?
In its 2026-Q2 13F filing, Samsara BioCapital, LLC reported 24 equity positions worth $1.22B in aggregate; its largest disclosed positions were SRRK ($379.37M), ALMS ($178.55M), MLYS ($158.40M).
How large is Samsara BioCapital, LLC's portfolio?
Samsara BioCapital, LLC reported $1.22B of long equity holdings across 24 positions as of 2026-Q2. Top-10 holdings account for 90.5% of reported value.
What is Samsara BioCapital, LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.